Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
Documents
DMF + FDA EIR
基本文件流程错误SQL调试用户
请求信息 : 2025-04-02 13:43:39 HTTP/1.1 GET : https://senovatech.com/anti_infection/189.html